Loading
Latest filing published 25 Mar 2026 for HYPHENS PHARMA INTERNATIONAL LIMITED, €6,273.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Chan Kiat on record concern Hyphens Pharma International Limited. Over a trading history stretching from 1 March 2024 to 23 March 2026, the count stands at 3 filings.
Every open-market trade on record is a purchase: 3 purchases worth €22k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2026, the count stands at 1 purchase and no sales.
Half of the purchases are above €6,273 and half below. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 3 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +3.7%. They describe history only and say nothing certain about the share price ahead.
The newest entry dates from 25 March 2026: an open-market purchase of €6,273, in Hyphens Pharma International Limited. The median gap between a trade and its publication by SGX is 5 days. That lag is the time during which only the insider knows about the trade. Every figure here comes from the filings published by SGX and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations